Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems Pemetrexed (PMX) is an antifolate drug utilized in the treatment of non-small cell lung cancer. For studies of potential macromolecular carriers for PMX, fast and precise methods were developed to determine the bound and free drug contained in investigated conjugate preparations. The analysis of the total amount of PMX in conjugates was based on absorption spectrophotometry. The linearity was found in the range of 4.697-46.97 μmol L -1 PMX. The limit of quantitation was 1.070 μmol L The proposed methods can be used both for the characterization of the polysaccharide based conjugates of PMX and for the determination of conjugate drug release profi les.
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The search for new, innovative methods of disease treatment, especially for cancer, is an ongoing challenge in both industry and academia. Conjugates composed of high molecular mass natural or synthetic polymers and antineoplastic agents may exhibit a range of positive features, such as increased half-life in an organism, increased stability, reduced immunogenicity and intensifi ed therapeutic effi cacy (1, 2) . The combination of drugs already used in therapy with high molecular carriers may lead to a new therapeutic quality (3).
Pemetrexed (PMX) is a multi-target antifolate. It is an antimetabolite of folic acid and the mechanism of its action is based on its ability to inhibit the activity of the enzymes involved in purine and pyrimidine synthesis: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamideribonucleotideformyl transferase (GARFT) (4). Aft er being transported into the cell via the reduced folate carrier or/and folate receptors, PMX is polyglutamated to the active pentaglutamide by a reaction catalyzed by polylpolyglutamate synthase (5) . PMX has a wide usage in the treatment of pleural mesothelioma (6), non-small cell lung cancer (7) and prostate cancer (8) . However, this drug demonstrates a range of disadvantages characteristic of low molecular compounds, such as fast metabolism and fast excretion from the organism, as well as adverse biodistribution and low selectivity of therapeutic use (9) . Moreover, its clinical use is limited by dose-dependent toxicity. Solving these problems involves the coupling of PMX with macromolecular carriers, resulting in enhancement of the delivery and selectivity and improvement of the pharmacological properties of PMX.
There have been numerous scientifi c reports concerning another antifolate drugmethotrexate (MTX) -conjugated with a polysaccharide based, high molecular mass carrier such as mannan (10) , dextranes (11) , hyaluronic acid (12) or hydroxyethyl starch (HES) (13) . In vivo studies have indicated that methotrexate conjugated with HES [a modifi ed polymer, based on amylopectin, used clinically as a colloidal plasma volume expander (14) ] exhibits high effi cacy for the treatment of experimental tumors. Studies of HES as a carrier for MTX, conducted in our laboratory, are currently being extended by experiments with PMX covalently bound (ester bond) with HES. In order to investigate the potential of HES-PMX conjugates, a fast and precise method is needed to determine the total and free drug contained in investigated conjugate preparations.
The aim of this study was to develop novel methods for the determination of PMX in macromolecular conjugates. These methods were then used for characterization of the HES-PMX conjugate.
EXPERIMENTAL

Materials
The pemetrexed standard was purchased from Eli Lilly (USA). Sodium bicarbonate, analytical grade, was obtained from Avantor Performance Materials (Poland). HES-PMX conjugates were obtained according to the previously described methods (11, 13) . The water used was produced by a Direct-Q3 UV system (Millipore, USA). 
Ultraviolet spectroscopy (UV)
All measurements were conducted on a Specord ® 250 (Analytic Jena, Germany) spectrophotometer at ambient temperature. UV spectra were recorded in the range 210-350 nm, with a slit width of 1 nm and scan speed of 50 nm s 
Size-exclusion chromatography
Ultimate 3000 HPLC system (Dionex, USA) was used equipped with a DAD detector connected to a Superdex ® 30 Peptide (GE Healthcare, UK) column (4.6 × 150 mm, 34 μm) at 22 °C. Sodium bicarbonate solution (0.1 mol L -1 ) was used as the mobile phase at a fl ow rate of 0.4 mL min -1 . UV detection was done at 225 nm; injection volume was 10 μL. It was validated according to the following parameters.
Specifi city. -Specifi city was determined by analyzing the chromatograms of hydroxyethyl starch in comparison with the chromatogram of a mixture of hydroxyethyl starch and pemetrexed to confi rm that none of the excipients interfered with quantitation of the drug.
Linearity and range. -Linearity of the methods was determined by measuring independent concentrations of the calibration standards of PMX.
The linearity of the method for the analysis of total PMX in preparations was determined by measuring fourteen independent concentrations (μmol L Accuracy. -In order to evaluate this parameter, three independent replicates of each sample (mixture of hydroxyethyl starch and pemetrexed) were measured and then compared to the theoretical concentration of PMX in the sample, with data calculated from the calibration curve. The result was presented as the percentage of recovery.
Precision. -Precision of the method was calculated by comparing the results for triplicates of one sample (mixture of hydroxyethyl starch and pemetrexed). The result was presented as RSD.
Limit of detection (LOD) and limit of quantitation (LOQ). -LOD was calculated based on a signal to noise ratio of 3:1 and LOQ based on a signal to noise ratio of 10:1. ). Samples (mixture of hydroxyethyl starch and pemetrexed) were determined in triplicate for each variation of the method conditions. Results were compared with the previously reported results.
Determination of pemetrexed in HES-PMX conjugates
The conjugate was dissolved in NaHCO 3 
) and the total PMX was measured by the spectrophotometric method. Based on this result, the conjugate was diluted with NaHCO 3 0.1 mol L -1 to a fi nal concentration of 223.0 μmol L -1 (total PMX) and analyzed for unbound PMX by the gel chromatographic method. In addition, a quantitative analysis of the PMX released from the HES-PMX conjugate was performed. The conjugate was completely hydrolyzed in NaOH (0.1 mol L -1 ) for 24 hours and then analyzed for unbound PMX by the chromatographic method. Total glucose contents in HES-PMX preparations were determined using the phenol-sulfuric acid method (15) .
Analysis of the HES-PMX conjugate with PMX standard addition
The conjugate and PMX standard were diluted in NaHCO 3 
) to a fi nal concentration of 339.9 μmol L -1 (total PMX 116.9 μmol L -1 was PMX standard) before chromato-graphic analysis of unbound PMX in preparations. The drug content determined according to the method were reduced by the amount of free drug in the HES-PMX conjugate, and then the statistical signifi cance was determined by Student's t-test.
RESULTS AND DISCUSSION
The analysis of total PMX in preparations was based on absorption spectrophotometry in 0.1 mol L -1 sodium bicarbonate at  = 225 nm. Results of the validation of the method are presented in Table I Unbound PMX in preparations was determined by size-exclusion chromatography.
Results of the validation of the method are presented in Table I . The results of specifi city showed that there was no interference at the retention time of the drug from a mixture of hydroxyethyl starch and PMX (Figs. 1a and b) . Moreover, the photodiode array detector indicated that the PMX peak was free from interference (purity index > 0.9999). Linearity concentration range was 2.230-223.0 μmol L -1 with a coeffi cient of determination of 0.9999. Accuracy of the method, expressed as recovery, was found to be 95.4-105.6 %. RSD was found to be 0.1-1.0 %. LOD and LOQ were found to be 0.1616 and 0.5386 μmol L ). The method was considered robust because the RSD values were lower than 0.9 %, as summarized in Table II . As expected, some variation in the retention time was observed, without compromising the drug content determination. The use of the standard addition method confi rmed confi dence interval of the added standard CI95 (116.3; 118.1; p = 0.8597).
Table I. Validation parameters for the analysis of PMX in macromolecular drug-carrier systems
Parameter
The method for the analysis of total PMX
The method for the analysis of unbound PMX Linearity (μmol L New methods have been used to determine both the overall and the covalently bound PMX in the HES-PMX conjugate. The conjugate contained 44.6 × 10 -3 covalently bound PMX residued per anhydroglucose unit and there was 0.7 % of free (unbound) PMX in the fi nal preparations (Table III, Figs. 2a and b) . In addition, consistent results were obtained for the quantitative analysis of total PMX (aft er complete release from the HES-PMX con- jugate) via size-exclusion chromatography and for the analysis of total PMX via absorption spectrophotometry (Table III) . The diff erence between these measurements did not exceed 1 % PMX (below RSD of both methods).
CONCLUSIONS
The proposed methods can be used both for the characterization of the polysaccharide based conjugates of PMX and for the determination of conjugate drug release profi les. 
